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1. Introduction
Urticaria, also known as hives, is a common pruritic skin disease which is characterized by 
erythematous and edematous papules and plaques. These lesions have a transient nature 
which means a single-lesion heals within 24 h but new lesions may occur recurrently. The 
disease may be idiopathic or inducible and it is called chronic when intermittent attacks last 
for more than 6 weeks [1].
The lifetime prevalence of urticaria is 10–20%, while this rate is approximately 2% in its 
chronic form [1, 2]. Urticaria can occur at any age but the chronic urticaria form is more com-
mon in adults. The disease can affect both genders but female predominance is evident [2].
Cutaneous mast cells and mediators that are released as a result of mast cell degranulation are 
located at the center of urticaria pathogenesis [3]. Triggering factors may cause mast cell degran-
ulation via different mechanisms such as direct activation or IgE-mediated allergic activation. 
The common outcomes are the release of mediators such as histamine and their clinical effects. 
Beside pruritus, these vasoactive mediators are responsible for vasodilation and subsequent ery-
thema and edema [3, 4]. Activation of mast cells in superficial dermis causes urticarial papules 
and plaques while angioedema occurs as a result of mast cell involvement in deeper tissues [5].
There are many triggering factors for urticaria but determining a specific cause is not always 
possible. This quest is more complicated in some cases, especially in chronic ones. In addition 
to classification as acute or chronic, the disease may also be defined with etiologic factors, 
such as physically induced, autoimmune, or idiopathic urticarial [6]. Drugs, viral, bacterial or 
parasitic infections, insect bites, foods, physical factors, autoimmune diseases, and emotional 
stress are leading causes in etiology [6, 7].
It is known that infections may cause urticaria but the mechanism is unclear [8]. It is also dif-
ficult to determine if the trigger was an infection or a drug used for the treatment of infection. 
Nonsteroidal anti-inflammatory drugs and antibiotics, especially beta lactams, constitute 
a significant proportion of drug etiology. These drugs mainly cause urticarial reaction via 
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IgE-mediated immunologic pathways [9]. In addition, some drugs such as vancomycin, nar-
cotic analgesics, barbiturates, neuromuscular blockers, and radiocontrast agents may cause 
 urticarial eruption via direct mast cell degranulation [9, 10]. Nonsteroidal anti-inflammatory 
drugs may also trigger urticaria by interfering with arachidonic acid metabolism via cyclo-
oxygenase 1 enzyme inhibition. This blockage leads to increased synthesis of cysteinyl leukot-
rienes. This form of urticarial reaction is called pseudoallergy [10].
Physically induced urticarias are thought to occur as a result of increased mast cell sensitiv-
ity to environmental stimuli. Physical factors that may trigger urticaria include ultraviolet 
light, pressure, vibration, exercise, water contact, cold or heat exposures, and increased body 
temperature [11].
Systemic diseases can also be the underlying cause of urticaria. Therefore, the presence of any 
accompanying systemic symptoms is significant. Autoimmune and rheumatologic diseases 
constitute the majority of this group [12]. Systemic diseases include cutaneous vasculitis, sys-
temic lupus erythematosus, celiac disease, diabetes mellitus, Sjögren's syndrome, rheumatoid 
arthritis, autoimmune thyroid disease, and mastocytosis [1, 12]. Malignancies may also trig-
ger urticaria and the disease tends to be persistent in this case [13].
Elementary lesion of urticarial eruption is papule or plaque with erythema and edema. 
Circumscribed, pink-to-red lesions elevated from the skin vary in size and shape. These 
plaques which may tend to merge with central pallor can affect any region of the body [14]. 
Pruritus is the main annoying symptom which mostly interferes with daily activities of the 
patients [15]. Although a single urticarial lesion is transient, repetitive character of the erup-
tion is a significant problem. Lesions persisting beyond 24 h with residual petechia or hyper-
pigmentation, especially if accompanied by systemic symptoms such as fever and arthralgia, 
may suggest urticarial vasculitis in differential diagnosis and warrant skin biopsy [16].
Angioedema may accompany urticaria if the mast cells in the deeper dermis and subcutane-
ous tissue were involved in reactions. When this occurs, the lips and eyelids are the regions 
mainly affected [1]. Urticaria may also be a component of severe systemic allergic reactions, 
anaphylaxis, and so patients should always be examined for accompanying signs and symp-
toms such as flushing, swollen lips and tongue, difficulty in breathing, hoarse voice, hypoten-
sion, dizziness, hypotonia, syncope, nausea, vomiting, abdominal pain, and incontinence [17].
Diagnosis of urticaria is mostly based on anamnesis and physical examination. Due to the 
transient nature of the rash, there may be no lesions during a doctor visit. In this case, the clin-
ical history of intensely pruritic lesions that heal within a few hours may be the only clue for 
urticaria diagnosis. In uncertain cases, asking patients to take a photo when they have a rash 
is a helpful method. It may be advisable to mark a single lesion and note the time it appeared 
and disappeared to determine the duration. Observation of characteristic erythematous and 
edematous papules and plaques supports the diagnosis. Association with angioedema and/or 
anaphylaxis should always be kept in mind and questioned [1, 2].
Skin biopsy is not indicated for the diagnosis of urticaria unless there is suspicion of urticarial 
vasculitis or mastocytosis. If vasculitis is suspected, an additional skin sample should be taken 
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for immunofluorescence examination. Histopathological findings of urticaria include intersti-
tial edema and perivascular mixed cellular infiltrate. T lymphocytes are predominant cells in 
this infiltrate but eosinophils, neutrophils, and basophils may also exist in a lesser extent [18]. 
Leukocytoclasis and fibrinoid necrosis of vessel walls are signs in favor of vasculitis [16].
Once the diagnosis is confirmed, it becomes important to find out triggering factors, if pos-
sible. Detailed anamnesis is important to determine any triggering medication, infection, or 
physical stimuli such as scratching, sunlight, pressure, heat or cold contact, exercise, and water. 
Challenge tests may be performed for the diagnosis of physical urticaria but caution should 
be exercised during the procedure because serious systemic allergic reactions can develop.
Autologous serum skin tests may be used to differentiate autoimmune urticaria, but patients 
should cease antihistamines at least 3 days prior to the procedure. In this subtype of urticaria, 
intradermal injection of patient’s own serum results in an urticarial reaction within 30 min [19].
It is not indicated to use laboratory tests for patients with acute urticaria unless they have 
signs and symptoms suggesting an underlying systemic disease [1]. In chronic cases, initial 
laboratory examinations may include complete blood count, fasting blood glucose, erythro-
cyte sedimentation rate, C-reactive protein, kidney and liver function tests, urinalysis, and 
total serum Immunoglobulin-E levels. Additional tests such as antinuclear antibody, rheuma-
toid factor, complement C
3
 and C
4
 levels, thyroid hormones and autoantibodies, serology of 
Hepatitis viruses, Helicobacter pylori antigen, and fecal parasite examination can be performed 
if an infectious disease or an autoimmune disease is suspected [1, 12].
After diagnosis, determining the severity of the disease becomes important to evaluate the treat-
ment response objectively. There are some scoring systems used for this purpose, one of which 
is the urticaria activity score (UAS). It is a widely used scoring system questioning the intensity 
of pruritus and the number of wheals in a day. Higher scores mean a more severe disease [20].
2. Conclusion
Generally, the disease is self-limited and it shows regression in a few weeks for most cases. 
Some patients may have persistent symptoms for months or years and the disease is consid-
ered chronic beyond 6 weeks.
If possible, the prevention of trigger is the first step of treatment. Treatment aim is to control 
symptoms with minimal side effects. H
1
 antihistamines are the drugs most commonly used 
for this purpose. Second-generation H
1
 antihistamines, such as cetirizine and loratadine, are 
used as first-line treatment options. These newer, non-sedative antihistamines are more pre-
ferred than first-generation ones such as hydroxyzine and diphenhydramine. First-generation 
antihistamines may have also the disadvantage of anticholinergic side effects in addition to 
their sedative effects. In unresponsive cases, dose increment up to fourfold of standard thera-
peutic doses is recommended by the latest guidelines [1, 21]. Increasing the dose of a particu-
lar antihistamine is thought to be superior to the combined use of multiple antihistamines at 
standard doses [21]. H
2
 antihistamines may be used in combination with H
1
 antihistamines.
Introductory Chapter: Urticaria
http://dx.doi.org/10.5772/intechopen.68997
5
Short-term systemic glucocorticoid therapy may be administered in addition to antihista-
mines for acute urticarial attacks, particularly when accompanied by angioedema [1]. Long-
term usage of systemic glucocorticoids is not recommended because of potential side effects.
Antileukotrienes, such as montelukast and zafirlukast, are generally added to antihistamines 
as second-line treatment options in chronic cases refractory to high-dose antihistamines. 
Immunosuppressive agents, especially cyclosporine, are efficient to treat chronic urticaria but 
potential side effects must always be kept in mind. Dapsone, hydroxychloroquine, sulfasalazine, 
and mycophenolate are other less recommended drugs for the treatment of urticarial [1, 21]. 
Omalizumab, which is a safer alternative to those mentioned above, has recently come to the 
forefront in the treatment of chronic urticaria. It is an anti-IgE monoclonal antibody which has 
a good efficacy and safety profile [22, 23]. It also has the ease of use with monthly subcutaneous 
injections.
Since chronic urticaria treatment may become complicated, treatment switch, or combination 
is not surprising for most cases.
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